Novartis has lost a bid to keep a generic version of its top-selling heart failure drug Entresto off the U.S. market by ...

With Friday’s ruling by New Jersey District Judge Zahid Quraishi, Novartis joins a growing list of pharmaceutical companies ...

The Committee for Medicinal Products for Human Use adopted a positive opinion for NVS' Kisqali to help reduce the risk of recurrence in people with HR+/HER2- early breast cancer.

European regulators have for the fourth time issued a negative opinion on PTC's Translarna. Elsewhere, Amylyx read out data ...

As a host of generics circle the gates, Novartis has lost another bid to waylay MSN Pharmaceuticals’ copycat of the Swiss ...

Novartis is paying Chengdu Baiyu Pharmaceutical $70 million to add to its crop of cancer candidates. | Novartis is paying ...

Novartis has terminated a phase 2 trial of its SMURF1 inhibitor LTP001 in idiopathic pulmonary fibrosis (IPF) but will ...

Two years after raiding the offices of Novartis, Switzerland’s Competition Commission (COMCO) has dropped its investigation ...

BP’s program includes a novel PSMA-binding molecule that may be a potential next-generation radioligand therapy (RLT) for prostate cancer and is currently being studied in two investigator-initiated ...

If approved, patients in Europe with stage II or III HR+/HER2- early breast cancer (EBC) at high risk of recurrence, including those with node-negative disease, will be eligible ...

Novartis' Kisqali receives a positive recommendation from EMA's CHMP for adjuvant treatment of early breast cancer, showing a ...

Novartis said the European Medicines Agency has recommended its Kisqali cancer drug for market authorization. The drugmaker said Friday that the EMA's Committee for Medicinal Products for Human Use ...